BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs. For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.
Biotech market activity remains robust, with recent IPOs like Parabilis and Kyverna demonstrating strong aftermarket performance despite broader geopolitical tensions and shifting policy at the Fed. The industry is simultaneously navigating the implications of the Biosecure Act, particularly following the Department of...
Biopharma industry developments center on the $2 billion acquisition of Candid Therapeutics by UCB, signaling a strategic shift toward T cell engagers for autoimmune applications. This move underscores the necessity of clinical proof-of-concept in a crowded landscape. Leukodystrophy research is simultaneously evolving,...
The FDA is proposing a new regulatory pathway to accelerate First-in-Human clinical trials by allowing non-animal, new approach methods to substitute for traditional toxicology requirements. While this initiative aims to reduce development time and costs, it faces significant hurdles, including the need for congression...
The podcast explores the biotech industry's resilience amid global uncertainties, focusing on M&A activity and potential impacts of the Middle East conflict. It highlights the sector's strong performance in the first quarter, driven by M&A deals and positive clinical readouts, but notes concerns about prolonged conflic...
The BioCentury This Week podcast explores how European biotech can compete in an era prioritizing speed in clinical data generation, particularly given the rise of China's biotech industry. The discussion highlights the need for Europe to streamline clinical trials and regulatory processes to remain competitive, addres...
The BioCentury This Week podcast covers recent developments in the biotech industry, including Arrowhead's progress towards becoming a large-cap biotech and Synnovation's $2 billion deal with Novartis. The discussion highlights Arrowhead's journey, from its nanotech origins to its current focus on RNAi therapeutics, em...
Follow this podcast in Podwise
Sign in to get AI summaries, transcripts and mind maps for any episode, including new ones.
